ArticleFrontiers in oncology2026
Correlation analysis of clinical efficacy and prognosis of endoscopic submucosal dissection of early gastric cancer with peripheral blood indexes.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the correlation between peripheral blood indicators and the clinical efficacy and prognosis of patients with early gastric cancer (EGC) undergoing endoscopic submucosal dissection (ESD). Methods: A single-center, retrospective cohort study was conducted on 120 EGC patients treated with ESD between January 2017 and August 2019. Patients were stratified into good (n=84) and poor (n=36) prognosis groups based on defined criteria. Univariate and multivariate logistic regression analyses were performed to identify factors influencing prognosis. The predictive performance of peripheral blood indicators was evaluated using receiver operating characteristic (ROC) curve analysis. Changes in biomarkers and patient-reported quality of life (assessed by QLQ-STO22) before and after ESD were compared, and their correlations were analyzed. Results: Univariate analysis revealed differences in Carbohydrate Antigen 19-9 (CA19-9), Carcinoembryonic Antigen (CEA), Neutrophil-to-lymphocyte ratio (NLR), Red blood cell distribution width (RDW), and Homocysteine (Hcy) levels between prognosis groups (all P<0.05). Multivariate analysis identified these five indicators as independent prognostic factors. ROC analysis demonstrated area under the curve (AUC) values of 0.723, 0.669, 0.757, 0.709, and 0.606 for CA19-9, CEA, NLR, RDW, and Hcy, respectively, in predicting prognosis. The combined model achieved an AUC of 0.950. Postoperative levels of all five biomarkers and QLQ-STO22 scores were lower than preoperative levels (all P<0.001). Furthermore, CA19-9, CEA, NLR, RDW, and Hcy showed positive correlations with QLQ-STO22 scores (all P<0.001). Conclusion: Peripheral blood indicators, particularly CA19-9, CEA, NLR, RDW, and Hcy, hold predictive value for the prognosis of EGC patients after ESD. Their postoperative reduction and positive correlation with quality-of-life scores suggest they reflect clinical efficacy. The combined use of these indicators provides the highest prognostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.